Tumor-cell-targeted peptides can bind to specific proteins (cell surface receptors, growth factor receptors, and cell adhesion molecules) on the tumor cell membrane or secreted from cells that promote tumor proliferation, invasion, migration, and migration, thus allowing drugs loaded on nanoparticles to have an anti-tumor effect. This evidence concerns the gene CD177 and neoplasm.